Be sure to catch up on the latest happenings in our winter newsletter here!
Newsroom
February 2, 2023
November 16, 2022
November 1, 2022
This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic strategies, and the evolving landscape of therapeutics and their impact on the disease. Specific areas of foci include monitoring for disease progression, effects on quality of life, and recent data on novel transthyretin gene silencers.
September 16, 2022
- Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28
- NTLA-2001 was generally well-tolerated at both dose levels
- Intellia to discuss data at investor event today, Friday, September 16, at 8:00 a.m. ET
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept.